NASDAQ:SUPN - Nasdaq - US8684591089 - Common Stock - Currency: USD
Taking everything into account, SUPN scores 7 out of 10 in our fundamental rating. SUPN was compared to 193 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making SUPN a very profitable company, without any liquidiy or solvency issues. SUPN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. These ratings would make SUPN suitable for value and quality investing!
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.6% | ||
ROE | 6.01% | ||
ROIC | 4.82% |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | 12.49% | ||
PM (TTM) | 9.27% | ||
GM | 89.75% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Altman-Z | 5.19 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 2.44 | ||
Quick Ratio | 2.26 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.89 | ||
Fwd PE | 13.42 |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | 11.09 | ||
EV/EBITDA | 6.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
32.34
-1.25 (-3.72%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | 11.89 | ||
Fwd PE | 13.42 | ||
P/S | 2.71 | ||
P/FCF | 11.09 | ||
P/OCF | 11.03 | ||
P/B | 1.76 | ||
P/tB | 4.4 | ||
EV/EBITDA | 6.54 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | 4.6% | ||
ROE | 6.01% | ||
ROCE | 7.83% | ||
ROIC | 4.82% | ||
ROICexc | 8.53% | ||
ROICexgc | N/A | ||
OM | 12.49% | ||
PM (TTM) | 9.27% | ||
GM | 89.75% | ||
FCFM | 24.45% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | 0 | ||
Debt/EBITDA | 0 | ||
Cap/Depr | 1% | ||
Cap/Sales | 0.12% | ||
Interest Coverage | -758.75 | ||
Cash Conversion | 100.39% | ||
Profit Quality | 263.83% | ||
Current Ratio | 2.44 | ||
Quick Ratio | 2.26 | ||
Altman-Z | 5.19 |